GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuroSense Therapeutics Ltd (NAS:NRSN) » Definitions » YoY EPS Growth

NeuroSense Therapeutics (NeuroSense Therapeutics) YoY EPS Growth : 40.74% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is NeuroSense Therapeutics YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. NeuroSense Therapeutics's YoY EPS Growth for the quarter that ended in Dec. 2023 was 40.74%.

NeuroSense Therapeutics's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.16.

NeuroSense Therapeutics YoY EPS Growth Historical Data

The historical data trend for NeuroSense Therapeutics's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroSense Therapeutics YoY EPS Growth Chart

NeuroSense Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
YoY EPS Growth
- -130.36 -151.94 -64.62 22.43

NeuroSense Therapeutics Quarterly Data
Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,900.00 -37.50 -41.94 140.00 40.74

NeuroSense Therapeutics YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

NeuroSense Therapeutics's YoY EPS Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EPS Growth (A: Dec. 2023 )
=(Earnings per Share (Diluted) (A: Dec. 2023 )-Earnings per Share (Diluted) (A: Dec. 2022 ))/ | Earnings per Share (Diluted) (A: Dec. 2022 ) |
=(-0.83--1.07)/ | -1.07 |
=22.43 %

NeuroSense Therapeutics's YoY EPS Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY EPS Growth (Q: Dec. 2023 )
=(Earnings per Share (Diluted) (Q: Dec. 2023 )-Earnings per Share (Diluted) (Q: Dec. 2022 )) / | Earnings per Share (Diluted) (Q: Dec. 2022 )) |
=(-0.16--0.27)/ | -0.27 |
=40.74 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuroSense Therapeutics YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of NeuroSense Therapeutics's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuroSense Therapeutics (NeuroSense Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuroSense Therapeutics Ltd (NAS:NRSN) » Definitions » YoY EPS Growth
Comparable Companies
FNCH CELZ CYCN LIXT BTTX ALRN CUBT EMMA TTNP RASP OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
11 HaMenofim Street, Building B, Herzliya, ISR, 4676670
Website
https://www.neurosense-tx.com
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.